Embedded Files
Clinical Classification of Autonomic Disorders
Clinical Classification of Autonomic Disorders
Isolated autonomic failure:
Autoimmune autonomic ganglionopathy
Paraneoplastic autonomic neuropathy
Progressive:
Pure autonomic failure
Progressive autonomic failure associated with parkinsonism, ataxia, or dementia:
Multiple system atrophy
Lewy body disorders (Parkinson disease, dementia with Lewy bodies)
Autonomic failure associated with peripheral neuropathy
Acute or subacute:
Guillain-Barré syndrome
Porphyria
Chronic acquired:
Diabetes
Amyloidosis
Immune (Sjögren disease, paraneoplastic)
Metabolic (vitamin B12 deficiency, uremia)
Toxic (alcohol, chemotherapeutic agents)
Infectious (HIV, leprosy)
Radiation therapy to neck
Hereditary:
Hereditary sensory and autonomic neuropathies
Fabry disease
Distal autonomic and painful neuropathies:
Acquired
Idiopathic
Inflammatory (vasculitis) or infectious (e.g., HIV)
Hereditary (e.g., familial erythromelalgia)
Focal central nervous system disorders (associated with autonomic failure or hyperactivity):
Insular stroke
Temporal lobe epilepsy
Limbic encephalitis
Fatal familial insomnia
Brainstem lesions
Spinal cord injury
Syringomyelia
Focal peripheral disorders:
Cranial disorders (gustatory sweating, harlequin syndrome)
Chronic regional pain syndrome
Syndromes of orthostatic intolerance:
Postural tachycardia syndrome
Neurally mediated (reflex) syncope
Primary disorders of sweating:
Essential anhidrosis
Primary focal hyperhidrosis
Drug-induced disorders:
Neuroleptic malignant syndrome
Serotonin syndrome
Anticholinergic toxicity
Alcohol withdrawal
Stimulant intoxication
Neuropathies with Autonomic Nervous System Involvement
Neuropathies with Autonomic Nervous System Involvement
Acute Neuropathies (4 weeks or less)
Acute panautonomic neuropathy (acute autonomic ganglionopathy)
Widespread failure of adrenergic and cholinergic systems
Orthostatic hypotension, xerostomia, anihidrosis, fixed heart rate, fixed pupils, and constipation.
Acute paraneoplastic autonomic neuropathy
Widespread failure of adrenergic and cholinergic systems
Orthostatic hypotension, anihidrosis, fixed heart rate.
Acute cholinergic neuropathy
Restricted to cholinergic failure
Xerostomia, anhidrosis, fixed HR, urinary retention.
Acute adrenergic neuropathy
Restricted to adrenergic failure
Adrenergic supersensitivity, HTN, postural tachycardia
Botulism
Cholinergic failure
Xerostomia, anhidrosis, fixed HR, urinary retention, ileus, orthostatic hypotension
Guillain-Barré syndrome
Cholinergic failure, adrenergic overactivity
Anhidrosis, tachycardia, hypo/hypertension
Porphyria
Adrenergic overactivity
HTN, tachycardia, piloerection
Toxic: vincristine, Vacor (rodenticide), cisplatin, amiodarone, heavy metals, etc.
Widespread adrenergic and cholinergic failure
Orthostatic hypotension, GI hypomotility, urinary retention.
Chronic Neuropathies (8 weeks or more)
Diabetes mellitus
Amyloid neuropathy (familial and primary)
Idiopathic panautonomia
Pure autonomic failure (PAF)
Paraneoplastic (LEMS)
Pure adrenergic neuropathy
Chronic idiopathic anhidrosis
Sjogren's syndrome
HSAN I
HSAN III (Riley-Day)
Distal small-fiber neuropathy
Sensory neuronopathy
Adie syndrome
Chagas disease
Dysautonomia of old age
Paraneoplastic sensory neuropathy (malignant inflammatory sensory polyganglionopathy)
Human immunodeficiency virus–related autonomic neuropathy
Orthostatic intolerance
POTS
Mild orthostatic intolerance
Syncope
Toxic
Organic Solvents (eg, n-Hexane)
Acrylamide
Heavy Metals (eg, Lead, Arsenic, Thallium, Mercury)
N-3-Pyridylmethyl-N′-p-Nitrophenyl Urea Rat Poison (of Historic Relevance)
Vinca alkaloids
Platinum derivatives
Taxanes
Epothilones
Bortezomib
Thalidomide, lenalidomide, pomalidomide
Doxorubicin
Cytosine arabinoside
Perhexiline maleate
Amiodarone
Pentamidine
Gold
Podophyllin
Marine Toxins (eg, Ciguatera)
Hereditary
Familial amyoidosis
HSAN (types 1-IV)
Fabry's disease
Tangier's disease
Mitochondrial disorders
The Clinical Evaluation In Autonomic dysfunction
Clinical Manifestations of Autonomic Failure | Output Consequences of Failure | Clinical Manifestation
Clinical Manifestations of Autonomic Failure | Output Consequences of Failure | Clinical Manifestation
Sympathetic vasomotor | Impaired baroreflex triggered vasoconstriction | Orthostatic hypotension, postprandial hypotension
Sympathetic sudomotor | Anhidrosis | Heat intolerance
Cranial parasympathetic | Impaired salivary and lacrimal secretion | Dry eyes (xerophthalmia), dry mouth (xerostomia)
Impaired pupillary light reflex | Blurred vision (impaired accommodation)
Sacral parasympathetic | Impaired output to the bladder, sexual organs, and rectum | Urinary retention, erectile dysfunction
Enteric nervous system | Impaired vagal control of the esophagus and stomach | Nausea and early satiety, abdominal distention
Impaired peristaltic reflexes | Constipation,
Impaired prevertebral ganglion reflexes | Ileus, diarrhea.
Autonomic Peripheral Neuropathy.pptxThe autonomic nervous system (ANS) is more than just a branch of the peripheral nerves - it’s a dynamic interface that links your brain’s fast neural commands with slower hormonal signals and even the immune response. Here’s how these three realms intertwine:
1. Nervous Roots and Rapid Signaling
○ The ANS splits into the sympathetic (“fight-or-flight”) and parasympathetic (“rest-and-digest”) branches, each sending electrical impulses along myelinated and unmyelinated fibers to organs, blood vessels, and glands.
○ Through neurotransmitters like norepinephrine and acetylcholine, it orchestrates instant adjustments in heart rate, digestion, pupil size, and more.
2. Endocrine Partnerships: From Brain to Bloodstream
○ Hypothalamic Control: The hypothalamus integrates stress or metabolic cues, then stimulates the pituitary gland to release ACTH, which in turn prompts the adrenals to secrete cortisol and adrenaline.
○ Sympathetic–Adrenal Medullary Axis: Direct sympathetic outflow to the adrenal medulla yields a rapid spike of epinephrine/norepinephrine, prolonging and amplifying neural signals via the bloodstream.
○ Parasympathetic Modulation of Insulin & Gut Hormones: Vagal tone enhances insulin release and gastric motility, linking “calm” signals with nutrient absorption and energy storage.
3. Immune Cross-Talk: The Neuro-Immune Reflex
○ Cholinergic Anti-Inflammatory Pathway: Acetylcholine released by vagal efferents directly dampens pro-inflammatory cytokine production in the spleen and other lymphoid tissues.
○ Sympathetic Immune Modulation: Norepinephrine can both boost and inhibit immune cell activity, depending on receptor subtype (β₂-adrenergic receptors often suppress inflammation, while α-adrenergic activation may enhance it).
○ Stress-Induced Immunosuppression: Chronic sympathetic overdrive and elevated cortisol can shunt energy away from immune defenses, increasing susceptibility to infection.
4. Integrated Outcomes & Health Implications
○ Allostatic Load: Repeated ANS–endocrine surges wear on tissues—hypertension, insulin resistance, and dampened immunity follow if recovery (parasympathetic activation) is insufficient.
○ Therapeutic Targets: Enhancing vagal tone (via breathing exercises, biofeedback, meditation) can recalibrate both hormonal cascades and inflammatory responses, illustrating the power of mind–body integration
After a bout of physiological stress—whether from intense exertion, illness, surgery, or trauma—the immune system undergoes an active, two-phase recalibration rather than simply returning to baseline. In the first phase, the body releases stress hormones like adrenaline and cortisol, which mobilize immune cells (such as neutrophils, monocytes, and NK cells) into circulation to enhance immediate defense and tissue repair. Once the stressor passes, the system enters a second, recovery phase where anti-inflammatory signals like IL-10 and sustained cortisol help temper the immune response, preventing excessive inflammation and allowing adaptive immunity (T and B cells) to take over. This coordinated reset not only promotes healing but safeguards against immune overdrive or exhaustion. While acute stress can temporarily sharpen immune vigilance, chronic or unrelieved stress disrupts this balance—potentially leading to suppression, persistent inflammation, or autoimmunity. Thus, post-stress immune function isn’t just about rebound—it’s an elegant recalibration toward homeostasis and protection.
Gangliopathy refers to a disorder affecting the ganglia, which are clusters of nerve cell bodies located in the peripheral nervous system. When these ganglia are damaged or dysfunctional, it can lead to various neurological conditions, including dysautonomia and sensory neuropathy.
Dysautonomia is a term used to describe a group of disorders that affect the autonomic nervous system (ANS). The ANS controls involuntary bodily functions such as heart rate, blood pressure, digestion, and temperature regulation. When the ganglia involved in the ANS are affected, it can result in symptoms such as:
Orthostatic hypotension (a significant drop in blood pressure upon standing)
Fainting or dizziness
Abnormal heart rate
Gastrointestinal issues (e.g., constipation, diarrhea)
Urinary problems
Sweating abnormalities
Sensory neuropathy involves damage to the sensory nerves, which are responsible for transmitting sensory information (such as pain, temperature, and touch) from the body to the brain. When ganglia associated with sensory nerves are affected, it can lead to symptoms such as:
Numbness or tingling in the extremities
Pain or burning sensations
Loss of coordination or balance
Sensitivity to touch
Autoimmune autonomic ganglionopathy (AAG) is a specific type of gangliopathy where the immune system mistakenly attacks the autonomic ganglia. This can lead to a range of dysautonomia symptoms, including severe orthostatic hypotension, gastrointestinal dysmotility, and dry mouth or eyes AAG is a rare condition, and its exact cause is not well understood.
In summary, gangliopathy can significantly impact both the autonomic and sensory nervous systems, leading to a variety of symptoms associated with dysautonomia and sensory neuropathy.
The clinical triad associated with ganglionic acetylcholine receptor antibodies-often seen in autoimmune autonomic ganglionopathy (AAG)-typically includes severe orthostatic hypotension, gastrointestinal dysmotility diarrhea/constipation, and dilated pupils. These symptoms reflect widespread dysfunction of the autonomic nervous system, which controls involuntary bodily functions. The presence of these antibodies, particularly in high titers, correlates with the severity of autonomic impairment. Patients may also experience dry mouth, dilated pupils, and fainting episodes, making the triad a useful but not exhaustive indicator of the broader clinical spectrum
In patients with suspected autoimmune or idiopathic ganglionopathy, both skin nerve biopsy and QSART may appear normal despite significant dysautonomia symptoms. This is because the primary pathology often targets the autonomic ganglia-the relay stations between central and peripheral autonomic pathways-rather than the postganglionic fibers directly assessed by these tests. Skin biopsy evaluates small fiber integrity and density, and QSART measures sweat output from postganglionic sympathetic fibers. If the ganglionic synapse is dysfunctional but downstream fibers are still anatomically intact, these tests can yield normal results. Therefore, normal findings don't exclude ganglionopathy, especially when clinical presentation strongly suggests autonomic dysfunction. In such cases, autonomic reflex screens, antibody panels, or tilt table testing may provide better diagnostic insight.
Even if skin nerve biopsy and QSART come back normal, a person can still have symptoms of dysautonomia due to ganglionopathy. These tests check the small nerves and sweat function after signals have already passed through the autonomic ganglia. But if the problem lies within those ganglia-the places where signals are relayed-then the downstream nerves might still look normal. So, normal test results don't rule out an issue. Other tests like tilt table or reflex screens might better reflect what's going on.
Autoimmune inflammatory neuropathy with autonomic and motor aspects presented as a subacute to chronic syndrome in which immune-driven inflammation targeted autonomic ganglia, small autonomic fibers, and motor peripheral nerves, producing a constellation of symptoms that included orthostatic intolerance, syncope or presyncope, gastrointestinal dysmotility, urinary dysfunction, abnormal sweating, and varying degrees of limb weakness or sensory loss; clinically it often combined features of autonomic failure (eg, orthostatic tachycardia or hypotension and GI dysautonomia) with motor deficits ranging from distal weakness to more diffuse motor involvement, and it could arise after infections, vaccinations, or in association with systemic autoimmune disease or paraneoplastic processes. Pathophysiologically, the disorder reflected autoimmune targeting of autonomic ganglia or small fibers-sometimes mediated by autoantibodies (eg, against ganglionic nicotinic acetylcholine receptors) or by cell-mediated inflammation-leading to impaired baroreflexes, altered sympathetic-parasympathetic balance, and small-fiber degeneration that explained pain, thermal dysesthesia, and autonomic instability; concomitant motor nerve inflammation produced demyelination or axonal loss with weakness and reduced reflexes
Complex, chronic dysautonomia with significant environmental and physiologic triggers; history of acute onset on 05/27/2023 with subsequent episodic symptoms including hypertension, tremors, dysarthria, temperature dysregulation, and cognitive changes.
- Symptoms exacerbated by physical activity, certain foods, medications, and environmental exposures (e.g., insecticides, air pollution); periods of partial remission followed by worsening sensitivity and functional decline.
- Recent IVIG therapy initiated on 05/18 with adverse reactions, including aseptic meningitis-like symptoms; home infusions approved with plan to start at 8-hour infusion duration.
- Neurologic exam today notable for changes in reflexes compared to prior exam in September of last year; persistent balance issues and paresthesias.
- Order additional labs to further evaluate for underlying autoimmune, autonomic, and mast cell-related etiologies.
- Discussed importance of slow and steady IVIG infusions to minimize side effects; advised against rapid infusions.
- Consider trial of pyridostigmine (Mestinon) to help stabilize autonomic function and improve stamina, pending lab results.
- Educated patient on the variable course of dysautonomia and the need for ongoing management; encouraged continuation of IVIG therapy with close monitoring for improvement over the next 3-6 months.
- Follow-up to review lab results and reassess treatment plan.
- Continue IVIG with home infusions at a slow, steady rate; a loading dose should not be used because slower treatment is better tolerated and causes fewer side effects.
- Give each IVIG infusion slowly, even if vials have different lot numbers; the dose should not be adjusted based on lot number changes.
- Expect IVIG benefit to take time; improvement may take about 3 to 6 months.
- Stay within your exercise/activity zone and do only what your body tolerates; gentler approaches such as weight machines or Pilates were recommended over pushing harder.
PLAN
IV IGG Benefits for Therapy
Neutralizing Autoantibodies: In autoimmune diseases, the body's immune system mistakenly attacks its own tissues. IVIG contains a diverse range of antibodies that can neutralize these harmful autoantibodies, reducing their ability to cause damage.
Modulating Immune Response: IVIG can alter the activity of various immune cells, including T cells, B cells, and macrophages. This modulation helps to reduce inflammation and the autoimmune attack on the body's tissues.
Blocking Immune Complexes: IVIG can bind to immune complexes (clusters of antigens and antibodies) and prevent them from depositing in tissues, which can cause inflammation and tissue damage.
Enhancing Regulatory T Cells: IVIG can increase the number and function of regulatory T cells, which play a crucial role in maintaining immune tolerance and preventing autoimmune responses.
Anti-inflammatory Effects: IVIG has anti-inflammatory properties that help reduce the overall inflammation in the body, which is a common feature of autoimmune diseases.
Overall, IVIG therapy helps to restore balance in the immune system, reduce autoimmune attacks, and alleviate symptoms associated with autoimmune disease
Pyridostigmine/mestinon is used for orthostatic disorders well. This medication though designed at first for myasthenia (you do not have myasthenia) works on the same chemical messenger of the autonomic system as does the myasthenia with the message to the muscle . The medication will help stimulate the the connection of the autonomic system and amplify the response and without raising the blood pressure.
Other benefits that can help gut function and dryness of mouth and eyes
Follow these instructions below:
Start with mestinon 60 mg daily
Week 1 and 2: one mestinon at bed
Week 3 and 4 : one pill after breakfast or lunch and one at bed
Week 5 and onward : if not better one pill after breakfast, one mid afternoon, and one at bed
Over time the team /medical provider can increase to 60 mg each dose of the day (increase each dose by every 2 weeks ). Maximum can be for total daily dose 180 mg daily.
:
FYI . It can take a few months about 4 months for full effectiveness of a medications . Be patient though can be a challenge since you have been ill for so long that we respect you want to feel better soon. Medications that work neurologically need time to keep modulation effect and reset what the body has done in a disorder and disease. Ongoing work of the medication and other aspects of self care, exercise, wellness, and mindfulness help along for medication effectiveness. In clinical trials for medications often are studies for 3-5 months to allow for full effectiveness to be noted and seen.
Here is the titration to follow to work up to the prescription label regimen. We start low to avoid side effects of nausea and diarrhea (actually most autonomic patients note normalization and improvement of the gut function
Keep monitoring your blood pressure. If the medication is helping you as many autonomicshould notice less fatigue, stabilizing blood pressure, less dizziness, less high heart rates spikes, better gut function, less dry mouth/eyes and better stamina.
Mestinon (pyridostigmine bromide) is primarily known for treating myasthenia gravis, but over the years it's also been explored as an off-label treatment option for conditions like POTS (Postural Orthostatic Tachycardia Syndrome) and dysautonomia. The rationale behind its use lies in its mechanism of action: as an acetylcholinesterase inhibitor, Mestinon prevents the breakdown of acetylcholine. Acetylcholine is the key neurotransmitter of the parasympathetic ("rest and digest") nervous system. By increasing its levels, the drug may help to rebalance the often overactive "fight or flight" (sympathetic) response seen in many dysautonomia and POTS patients, potentially reducing some of the characteristic symptoms such as excessive tachycardia and blood pooling.
Because dysautonomia represents a wide spectrum of dysfunction in the autonomic nervous system-with patients experiencing symptoms ranging from lightheadedness and fatigue to severe orthostatic intolerance-the response to Mestinon can vary widely. Some patients have reported improvements in heart rate control, enhanced blood flow, and better overall autonomic balance
Google Sites
Report abuse